Brepocitinib Overview & RVT-3101 Update
Efficacy Data from a Phase 2b, Randomized Clinical Trial of Tapinarof
Cream for the Treatment of Atopic Dermatitis
Response rates: 49% of patients achieved IGA response and 51% of patients achieved EASI75 response at week 8
IGA Score 0 or 1 and ≥2-Grade Improvement at Week 8
Primary Endpoint was at 12 Weeks: Assessed in ITT Population
EASI75 at Week 8
Secondary Endpoint was at 12 Weeks: Assessed in ITT
Proportion of Patients
(NRI Analysis)
60%
Tapinarof 1% BID (n=40)
Tapinarof 1% QD (n=41)
-Tapinarof 0.5% BID (n=43)
50%
Tapinarof 0.5% QD (n=41)
Vehicle BID (n=42)
40%
Vehicle QD (n=40)
30%
20%
10%
Population (NRI Analysis)
70%
-Tapinarof 1% BID (n=40)
Week 8
*
Tapinarof 1% QD (n=41)
49%
*
60%
Tapinarof 0.5% BID (n=43)
Tapinarof 0.5% QD (n=41)
*
13%
Proportion of Patients
50%
Vehicle BID (n=42)
Vehicle QD (n=40)
40%
30%
20%
10%
Week 8
51%
18%
0%
0%
Week 1
Week 2
Week 4
Week 8
Week 12
Week 1
Week 2
Week 4
Week 8
Week 12
Japanese partner has also reported positive topline IGA and EASI75 results in Phase 3 trial for tapinarof in AD
roivant
19
*Difference vs vehicle is statistically significant at p-value of 0.05 or lower. NRI analysis to account for higher dropout rates in vehicle group. BID, twice daily; IGA, Investigator Global Assessment; EASI, Eczema Area and Severity Index; ITT, intention to treat;
NRI, non-responder imputation; QD, once daily.
For investor audiences onlyView entire presentation